Zobrazeno 1 - 10
of 429
pro vyhledávání: ''
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to
Autor:
Jonn Wu, Cheryl Ho, Zamzam Al-Hashami, Bonnie Leung, S. Moore, Selina K. Wong, Alexandra Pender, Ying Wang, Aria Shokoohi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC) has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The study goal was to assess the effect of molecular testing and the introduc
Autor:
Adrian C. L. Kee, Yu Yang Soon, Yvonne Ang, Alvin Wong, Folefac Aminkeng, Sen Hee Tay, Ross A. Soo, Boon Cher Goh, Yiqing Huang
Publikováno v:
International Journal of Cancer. 150:636-644
Immune-related adverse events (IrAEs) of immune checkpoint inhibitors (ICIs) can be serious and unpredictable. We examine the incidence rate and risk factors for IrAEs in an Asian cohort of nonsmall cell lung cancer (NSCLC) patients treated with immu
Autor:
Xiangjuan Ma, Di Wu, Jieran Long, Guangming Tian, Jian Fang, Jindi Han, Yang Wang, Ziran Zhang, Jie Zhang, Jun Nie, Weiheng Hu, Sen Han, Ling Dai, Xiaoling Chen
Publikováno v:
Cancer Immunology, Immunotherapy
Background The combination of PD-1/PD-L1 inhibitor and chemotherapy has been clinically confirmed to be beneficial as the first-line treatment of patients with advanced NSCLC. This study aimed to assess the effect of nivolumab + docetaxel versus nivo
Autor:
Giampiero Porzio, Luigi Della Gravara, Carlo Genova, Danilo Rocco, Luca Cantini, Sebastiano Buti, Sergio Bracarda, Marco Filetti, Alessandro Tuzi, R. Bisonni, Giulio Metro, Claudia Bareggi, Francesco Grossi, Francesca Mazzoni, Alfredo Addeo, David J. Pinato, Emilio Bria, Giovanni Mansueto, Vincenzo Adamo, Joachim G.J.V. Aerts, Raffaele Giusti, Diego Signorelli, Alessio Cortellini, Miriam Grazia Ferrara, Giorgia Guaitoli, Lorenza Landi, Corrado Ficorella, Gabriele Minuti, Fabiana Perrone, Fabrizio Citarella, Melissa Bersanelli, Giuseppe Luigi Banna, Emanuela Olmetto, Marina Chiara Garassino, Marco Siringo, Alain Gelibter, Michele De Tursi, Marco Russano, Giulia Mazzaschi, Gian Paolo Spinelli, Vincenzo Sforza, Luca Carmisciano, Rita Chiari, Katia Cannita, Fabrizio Tabbò, Diego Cortinovis, Alessandro De Toma, Serena Ricciardi, Stefania Gori, Olga Nigro, Mariangela Torniai, Rossana Berardi, Marcello Tiseo, Maria Rita Migliorino, Fausto Barbieri, Alessandro Follador, Alessandro Russo, Massimo Di Maio, Pietro Di Marino, Alex Friedlaender, Federica Zoratto
Publikováno v:
European Journal of Cancer, 150, 224-231. Elsevier Ltd.
Background: We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a drug-based prognostic
Autor:
Emma Hudson, Amerah Amin, Jason Francis Lester, Vaneet Nayar, Xiaohui Zhuo, Adeline Durand, Peter Martin, Andrew Conn, Ceri Powell, C. Escriu, Lauren Nelless, Samuel Chan, Xinke Zhang, Vivek Pawar, Talal Mansy, John Conibear, Juliet Brock, Sarah Khan
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical outcomes in
Autor:
Mandeep Banwait, Heather A. Wakelee, Maya N. White, Lecia V. Sequist, Zofia Piotrowska, Joel W. Neal, Stephen V. Liu, Kristen M. Cunanan, Daniel Hausrath, Kevin Stirling
Publikováno v:
Clin Lung Cancer
Background Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has improved survival and central nervous system (CNS) outcomes in patients with non–small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is
Autor:
Shidai Jin, Renhua Guo, Fangyan Gao, Liang Chen, Zhihong Zhang, Qianqian Wang, Jingya Zhang, Wen Gao, Fan Lin, Chen Zhang, Tianyu Qu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients har
Autor:
Josef Vodicka, Gabriela Krakorova, Jiri Blazek, Zuzana Teufelova, Magda Barinova, Karolina Hurdalkova, Marcela Buresova, Martin Svaton, Ondrej Topolcan, Miloš Pešek
Publikováno v:
Anticancer Research. 41:2053-2058
Aim To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with beva
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby